Last reviewed · How we verify

NCT03613636: myCAP

Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)

Completed Last updated 22 February 2024
What this trial tests

trial testing Enzyme-linked immunospot (ELISpot) assay [Blood] in Childhood Pneumonia in 490 participants. Completed in 31 October 2020.

Timeline
1 May 2016
Primary endpoint
31 October 2020
31 October 2020

Quick facts

Lead sponsorUniversity Children's Hospital, Zurich
StatusCompleted
Study typeOBSERVATIONAL
Enrollment490
Start date1 May 2016
Primary completion31 October 2020
Estimated completion31 October 2020

Drugs / interventions tested

Conditions studied

Sponsor

University Children's Hospital, Zurich

Who can join

3 and older, any sex, with Childhood Pneumonia or Mycoplasma Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and serology, in a cohort of children with community-acquired pneumonia (CAP) and controls.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Children's Hospital, Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03613636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing